RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback